Physician profile
Joy E Mclain
NPI 1730480724
$2,235.63
in general payments reported to CMS, 2019-2025
20 companies · $799 in 2025
The $799 reported for 2025 was more than what 94% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $255 · 2023: $438 · 2024: $468 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $234.32 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $171.15 | 2023-2025 | Myfembree |
| Astrazeneca Pharmaceuticals LP | $164.04 | 2021-2023 | Lokelma |
| Sage Therapeutics, LLC | $158.12 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $152.21 | 2023-2025 | Slynd |
| Shield Therapeutics INC | $151.01 | 2023-2025 | Accrufer |
| Novo Nordisk INC | $131.46 | 2021-2023 | Novoseven |
| Organon LLC | $128.43 | 2024-2025 | Nexplanon, Jada System |
| Abbvie INC. | $121.01 | 2023-2025 | |
| Genentech USA, INC. | $113.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $101.45 | 2022 | |
| Gilead Sciences, INC. | $97.13 | 2025 | Epclusa |
| Astellas Pharma US INC | $86.37 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.03 | 2022 | |
| Corcept Therapeutics | $77.70 | 2024 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $73.42 | 2022 | |
| Supernus Pharmaceuticals, INC. | $63.90 | 2025 | Qelbree |
| Pfizer INC. | $57.70 | 2023-2025 | |
| Boston Scientific Corporation | $56.88 | 2025 | General - Female Sui |
| Merck Sharp & Dohme LLC | $15.31 | 2023 | Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.